Montgomery County Showcases Its Unique Ecosystem at World Vaccine Congress 2026
Montgomery County, MD is commonly known as being a suburb of the nation’s capital, but what might surprise some is that it is also home to a thriving biotech ecosystem. With over 350 life sciences companies, including global brands like AstraZeneca, United Therapeutics, and Novavax, Montgomery County anchors the third largest biophama hub in the U.S., behind only Boston and San Francisco.
Running annually in Washington D.C. for over 25 years, World Vaccine Congress attracts an international audience from over 80 countries and convenes more than 3,000 people to learn about the latest trends, research, and technologies in the vaccine industry. This year, Montgomery County took center stage, with a featured session on the extensive Biologics Value Chain in the County, as well as a session during which County Executive Marc Elrich spoke about the extensive resources available to companies here, and an exhibit space showcasing these resources.
A Complete Biologics Value Chain in One Region
One of the defining strengths of Montgomery County is its ability to support the full lifecycle of biologics, all the way from early research to large-scale manufacturing. During the panel discussion, moderated by Dr. Stefanie Trop, Director of Life Sciences at the Maryland Department of Commerce, local leaders emphasized that the region’s strength lies in its network of partners who work collaboratively across discovery, development, testing, and production. Panelists from companies in all stages of the value chain spectrum included Dr. Andrew Lees, Founder of Fina Biosolutions, Benjamin Moutier, Senior Vice-President, Vaccines and Immune Therapies at AstraZeneca, Dr. Helen Sabzevari President & CEO of Precigen, and Dr. Frederick Holtsberg, Chief Scientific Officer of Integrated BioTherapeutics.
This end-to-end capability in close geographical proximity gives companies a unique advantage and is rare to find in other markets, even established ones like San Francisco and Boston. In fact, only a handful of places worldwide offer the combination of infrastructure, expertise, and collaboration found in Montgomery County and if diversity, education and population density are taken into consideration – then Montgomery County standouts even more.
“Gaithersburg is one of the six places in the world where we can do what we’re doing,” explained Benjamin Moutier, Senior Vice-President, Vaccines and Immune Therapies, AstraZeneca. “We have the right partners at every step of the value chain [in Montgomery County].”
A Strong Partnership Network
Biotech breakthroughs rarely happen in isolation. They depend on strong partnerships between private companies, local and state governments, academic institutions, and workforce training organizations. Montgomery County has intentionally cultivated these connections, making collaboration and coordination defining characteristics of its life sciences ecosystem.
Dr. Frederick Holtsberg, Chief Scientific Officer at IBT Bioservices, a full service CRO offering clinical & preclinical contract research services, says the company’s close partnerships between them and local stakeholders have been crucial to its success. “As a Rockville-based company, we’re grateful for the partnership and support from city, County, and state leaders,” explained Dr. Holtsberg. “These programs have helped fuel our growth, and we’re excited about the continued momentum of our community.”
Local partnerships also allow companies to scale rapidly, from early discovery to global distribution. This collaborative environment enables smaller companies to access the expertise and infrastructure typically available only to large organizations, allowing innovative therapies to reach patients more quickly.
“Montgomery County stands out as a place where patients are truly at the center of everything,” explained Dr. Helen Sabzevari, President & CEO of Precigen, a Germantown-based biotech company focused on developing therapies for immuno-oncology, autoimmune disorders, and infectious diseases. “There is a shared commitment across state, County, and industry to not only build and scale the right infrastructure, but to do so with excellence and urgency for those who need care.”
Building the Future of Biologics
As the biotech industry continues to evolve, companies are searching for where to put down roots and build. For many, Montgomery County offers the right combination of strategic location, talent, and infrastructure to thrive.
“Overall, the environment here is quite business friendly,” added Moutier. “Speaking as a global company, when we decide where we’re going to invest, we decide based on a number of factors—talent pool is critical—but also whether the location is business friendly. That’s the kind of relationship we have with the state of Maryland.”
